Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial.
Antibiotic prescription
Antimicrobial resistance
Febrile illness
Outpatient fever management
Randomized controlled trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Nov 2020
25 Nov 2020
Historique:
received:
04
08
2020
accepted:
12
11
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
10
6
2021
Statut:
epublish
Résumé
The management of acute febrile illnesses places a heavy burden on clinical services in many low- and middle-income countries (LMICs). Bacterial and viral aetiologies of acute fevers are often clinically indistinguishable and, in the absence of diagnostic tests, the 'just-in-case' use of antibiotics by many health workers has become common practice, which has an impact on drug-resistant infections. Our study aims to answer the following question: in patients with undifferentiated febrile illness presenting to outpatient clinics/peripheral health centres in LMICs, can we demonstrate an improvement in clinical outcomes and reduce unnecessary antibiotic prescription over current practice by using a combination of simple, accurate diagnostic tests, clinical algorithms, and training and communication (intervention package)? We designed a randomized, controlled clinical trial to evaluate the impact of our intervention package on clinical outcomes and antibiotic prescription rates in acute febrile illnesses. Available, point-of-care, pathogen-specific and non-pathogen specific (host markers), rapid diagnostic tests (RDTs) included in the intervention package were selected based on pre-defined criteria. Nine clinical study sites in six countries (Burkina Faso, Ghana, India, Myanmar, Nepal and Uganda), which represent heterogeneous outpatient care settings, were selected. We considered the expected seasonal variations in the incidence of acute febrile illnesses across all the sites by ensuring a recruitment period of 12 months. A master protocol was developed and adapted for country-specific ethical submissions. Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies of acute febrile illnesses in each country. We included a qualitative evaluation of drivers and/or deterrents of uptake of new diagnostics and antibiotic use for acute febrile illnesses. Sample size estimations were based on historical site data of antibiotic prescription practices for malarial and non-malarial acute fevers. Overall, 9 semi-independent studies will enrol a minimum of 21,876 patients and an aggregate data meta-analysis will be conducted on completion. This study is expected to generate vital evidence needed to inform policy decisions on the role of rapid diagnostic tests in the clinical management of acute febrile illnesses, with a view to controlling the rise of antimicrobial resistance in LMICs. Clinicaltrials.gov NCT04081051 . Registered on 6 September 2019. Protocol version 1.4 dated 20 December 2019.
Sections du résumé
BACKGROUND
BACKGROUND
The management of acute febrile illnesses places a heavy burden on clinical services in many low- and middle-income countries (LMICs). Bacterial and viral aetiologies of acute fevers are often clinically indistinguishable and, in the absence of diagnostic tests, the 'just-in-case' use of antibiotics by many health workers has become common practice, which has an impact on drug-resistant infections. Our study aims to answer the following question: in patients with undifferentiated febrile illness presenting to outpatient clinics/peripheral health centres in LMICs, can we demonstrate an improvement in clinical outcomes and reduce unnecessary antibiotic prescription over current practice by using a combination of simple, accurate diagnostic tests, clinical algorithms, and training and communication (intervention package)?
METHODS
METHODS
We designed a randomized, controlled clinical trial to evaluate the impact of our intervention package on clinical outcomes and antibiotic prescription rates in acute febrile illnesses. Available, point-of-care, pathogen-specific and non-pathogen specific (host markers), rapid diagnostic tests (RDTs) included in the intervention package were selected based on pre-defined criteria. Nine clinical study sites in six countries (Burkina Faso, Ghana, India, Myanmar, Nepal and Uganda), which represent heterogeneous outpatient care settings, were selected. We considered the expected seasonal variations in the incidence of acute febrile illnesses across all the sites by ensuring a recruitment period of 12 months. A master protocol was developed and adapted for country-specific ethical submissions. Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies of acute febrile illnesses in each country. We included a qualitative evaluation of drivers and/or deterrents of uptake of new diagnostics and antibiotic use for acute febrile illnesses. Sample size estimations were based on historical site data of antibiotic prescription practices for malarial and non-malarial acute fevers. Overall, 9 semi-independent studies will enrol a minimum of 21,876 patients and an aggregate data meta-analysis will be conducted on completion.
DISCUSSION
CONCLUSIONS
This study is expected to generate vital evidence needed to inform policy decisions on the role of rapid diagnostic tests in the clinical management of acute febrile illnesses, with a view to controlling the rise of antimicrobial resistance in LMICs.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov NCT04081051 . Registered on 6 September 2019. Protocol version 1.4 dated 20 December 2019.
Identifiants
pubmed: 33239106
doi: 10.1186/s13063-020-04897-9
pii: 10.1186/s13063-020-04897-9
pmc: PMC7687811
doi:
Banques de données
ClinicalTrials.gov
['NCT04081051']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
974Subventions
Organisme : Swiss Agency for Development and Cooperation, Global Health Division
ID : 810571721
Références
PLoS Negl Trop Dis. 2013 Jul 18;7(7):e2324
pubmed: 23875053
S Afr Med J. 2015 Apr 06;105(5):325
pubmed: 26242647
Zhonghua Gan Zang Bing Za Zhi. 2014 Oct;22(10):781-91
pubmed: 25558501
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
Injury. 2010 Jul;41 Suppl 1:S3-6
pubmed: 20466367
PLoS One. 2014 Apr 22;9(4):e95868
pubmed: 24755844
J Pediatric Infect Dis Soc. 2016 Jun;5(2):190-205
pubmed: 27059657
Sci Rep. 2020 Feb 7;10(1):2080
pubmed: 32034188
J Glob Infect Dis. 2019 Jan-Mar;11(1):36-42
pubmed: 30814834
N Engl J Med. 2014 Feb 27;370(9):809-17
pubmed: 24571753
Clin Microbiol Infect. 2019 Jan;25(1):20-25
pubmed: 29625170
PLoS Negl Trop Dis. 2020 Apr 30;14(4):e0008268
pubmed: 32352959
Lancet Infect Dis. 2014 Mar;14(3):239-49
pubmed: 24332389
PLoS Negl Trop Dis. 2020 Jan 10;14(1):e0007927
pubmed: 31923174
Lancet Glob Health. 2013 Jul;1(1):e46-54
pubmed: 24748368